Features of the relationship between clinical and laboratory, ultrasound signs of atherosclerosis and antioxidant defense in patients with comorbid pathology
- Authors: Polyakov V.Y.1, Kovrigin I.I1, Kozhin P.M1, Nikolaev Y.A1, Malov A.S1, Sevostyanova E.V1, Menschikova E.B1
-
Affiliations:
- Federal Research Center for Fundamental and Translational Medicine
- Issue: Vol 7, No 9 (2021)
- Pages: 76-84
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288639
- DOI: https://doi.org/10.18565/therapy.2021.9.76-84
- ID: 288639
Cite item
Abstract
Full Text
About the authors
V. Ya Polyakov
Federal Research Center for Fundamental and Translational Medicine
Email: vpolyakov15@mail.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
I. I Kovrigin
Federal Research Center for Fundamental and Translational Medicine
Email: ahiues9@bk.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
P. M Kozhin
Federal Research Center for Fundamental and Translational Medicine
Email: kozhinpm@centercem.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
Yu. A Nikolaev
Federal Research Center for Fundamental and Translational Medicine
Email: nicol@centercem.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
A. S Malov
Federal Research Center for Fundamental and Translational Medicine
Email: malov_as@cnmt.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
E. V Sevostyanova
Federal Research Center for Fundamental and Translational Medicine
Email: luck.nsk@rambler.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
E. B Menschikova
Federal Research Center for Fundamental and Translational Medicine
Email: lemen@centercem.ru
630117, Novosibirsk, 2 Timakova Str. Tel.: +7 (963) 942-35-25
References
- Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006; 47(8 Suppl): 07-12. doi: 10.1016/j.jacc.2005.09.068.
- Rafieian-Kopaei M., Setorki M., Doudi M. et al. Atherosclerosis: Process, indicators, risk factors and new hopes. Int J Prev Med. 2014; 5(8): 927-46.
- Зенков Н.К., Колпаков А.Р., Меньщикова Е.Б. Редокс-чувствительная система Keap1/Nrf2/ARE как фармакологическая мишень при сердечно-сосудистой патологии. Сибирский научный медицинский журнал. 2015; 5: 5-25. @@Zenkov N.K., Kolpakov A.R., Menshchikova E.B. The redox-sensitive Keap1/Nrf2/ARE system as a pharmacological target in cardiovascular pathology. Sibirskiy nauchnyy medicinsky zhurnal = Siberian Scientific Medical Journal. 2015; 5: 5-25 (In Russ.).
- Tian C., Gao L., Zucker I.H. Regulation of Nrf2 signaling pathway in heart failure: Role of extracellular vesicles and non-coding RNAs. Free Radic Biol Med. 2021; 167: 218-31. doi: 10.1016/j.freeradbiomed.2021.03.013.
- Souilhol C., Harmsen M.C., Evans P.C., Krenning G. Endothelial-mesenchymal transition in atherosclerosis. Cardiovasc Res. 2018; 114(4): 565-77. doi: 10.1093/cvr/cvx253.
- Kloska D., Kopacz A., Piechota-Polanczyk A. et al. Nrf2 in aging - focus on the cardiovascular system. Vascul Pharmacol. 2019; 112: 42-53. doi: 10.1016/j.vph.2018.08.009.
- Wei Y., Gong J., Thimmulappa R. K. et al. Nrf2 acts cell-autonomously in endothelium to regulate tip cell formation and vascular branching. Proc Natl Acad Sci USA. 2013; 110(41): E3910-18. doi: 10.1073/pnas.1309276110.
- Ahmed S.M.U., Luo L., Namani A. et al. Nrf2 signaling pathway: Pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017; 1863(2): 585-97. doi: 10.1016/j.bbadis.2016.11.005.
- Holloway P.M., Gillespie S., Becker F. et al. Sulforaphane induces neurovascular protection against a systemic inflammatory challenge via both Nrf2-dependent and independent pathways. Vascul Pharmacol. 2016; 85: 29-38. doi: 10.1016/j.vph.2016.07.004.
- Takabe W., Warabi E., Noguchi N. Anti-atherogenic effect of laminar shear stress via Nrf2 activation. Antioxid Redox Signal. 2011; 15(5): 1415-26. doi: 10.1089/ars.2010.3433.
- Zhang Z., Zhou S., Jiang X. et al. The role of the Nrf2/Keap1 pathway in obesity and metabolic syndrome. Rev Endocr Metab Disord. 2015; 16(1): 35-45. doi: 10.1007/s11154-014-9305-9.
- Sachdeva A., Cannon C.P., Deedwania P.C. et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136.905 hospitalizations in get with the guidelines. Am Heart J. 2009; 157(1): 111-17.e2. doi: 10.1016/j.ahj.2008.08.010.
- Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004; 109(23 Suppl 1): III2-7. doi: 10.1161/01.CIR.0000131511.50734.44.
- Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43(9): 1363-79. doi: 10.1194/jlr.r200004-jlr200.
- Kwiterovich P.O. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002; 90(8A): 30i-47i. doi: 10.1016/s0002-9149(02)02749-2.
- Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol. 2010; 21(4): 305-11. doi: 10.1097/ MOL.0b013e32833b7756.
- Abdolmaleki F., Hayat S.M.G., Bianconi V. et al. Atherosclerosis and immunity: A perspective. Trends Cardiovasc Med. 2019; 29(6): 363-71. doi: 10.1016/j.tcm.2018.09.017.
- Lacolley P., Regnault V., Nicoletti A. et al. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012; 95(2):194-204. doi: 10.1093/cvr/cvs135.
- Badran A., Nasser A. S., Mesmar J. et al. Reactive oxygen species: Modulators of phenotypic switch of vascular smooth muscle cells. Int J Mol Sci. 2020; 21(22): 8764. doi: 10.3390/ijms21228764.
- Ashino T., Yamamoto M., Yoshida T., Numazawa S. Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 2013; 33(4): 760-68. doi: 10.1161/ATVBAHA.112.300614.
- Cheng C., Haasdijk R. A., Tempel D. et al. PDGF-induced migration of vascular smooth muscle cells is inhibited by heme oxygenase-1 via VEGFR2 upregulation and subsequent assembly of inactive VEGFR2/PDGFRB heterodimers. Arterioscler Thromb Vasc Biol. 2012; 32(5): 1289-98. doi: 10.1161/ATVBAHA.112.245530.
- Генкель Б.Б., Салашенко А.О., Алексеева О.А., Шапошник И.И. Комплексная оценка сосудистой жесткости у больных атеросклерозом периферических артерий. Атеросклероз и дислипидемии. 2016; 4: 49-56. [Genkel B.B., Malashenko A.O., Alekseeva O.A., Shaposhnik I.I. Complex assessment of vascular stiffness in patients with atherosclerosis of peripheral arteries. Ateroskleroz i dislipidemii = Atherosclerosis and dyslipidemia. 2016; 4: 49-56 (In Russ.)].
- Ding Y., Zhang B., Zhou K. et al. Dietary ellagic acid improves oxidant-induced endothelial dysfunction and atherosclerosis: role of Nrf2 activation. Int J Cardiol. 2014; 175(3): 508-14. doi: 10.1016/j.ijcard.2014.06.045.
- Hur K.Y., Kim S.H., Choi M.A. et al. Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. Atherosclerosis. 2010; 211(1): 69-76. doi: 10.1016/j.atherosclerosis.2010.01.035.
- Zenkov N.K., Kozhin P.M., Chechushkov A.V. et al. Mazes of Nrf2 regulation. Biochemistry (Moscow). 2017; 82(5): 556-64. doi: 10.1134/ s0006297917050030.
- Liu T., Lv Y.F., Zhao J.L. et al. Regulation of Nrf2 by phosphorylation: Consequences for biological function and therapeutic implications. Free Radic Biol Med. 2021; 168: 129-41. doi: 10.1016/j.freeradbiomed.2021.03.034.
- Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473(7347): 317-25. doi: 10.1038/nature10146.
- Itabe H., Sawada N., Makiyama T., Obama T. Structure and dynamics of oxidized lipoproteins in vivo: Roles of high-density lipoprotein. Biomedicines. 2021; 9(6): 655. doi: 10.3390/biomedicines9060655.